Preclinical evaluation of a new liposomal formulation of cisplatin, lipoplatin, to treat cisplatin-resistant cervical cancer

Gynecologic Oncology

Volumn 131, Issue 3, 2013, Pages 744-752

  Casagrande, Naike ^a   De Paoli, Monica ^a   Celegato, Marta ^a   Borghese, Cinzia ^a   Mongiat, Maurizio ^a   Colombatti, Alfonso ^a,b   Aldinucci, Donatella ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

Author keywords

Cancer stem cells; Cervical cancer; Cisplatin resistance; Liposomal cisplatin; Migration; Spheroids

Indexed keywords

CASPASE 3; CASPASE 9; CISPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; LIPOPLATIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; THIOREDOXIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DNA FRAGMENTATION; DOWN REGULATION; DRUG ACCUMULATION; DRUG FORMULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EVALUATION; FEMALE; FLOW CYTOMETRY; HUMAN; IC 50; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; MULTICELLULAR SPHEROID; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR MICROENVIRONMENT; TUMOR SPHEROID; TUMOR VOLUME; TUMOR XENOGRAFT; UPREGULATION; UTERINE CERVIX CANCER;

CANCER STEM CELLS; CERVICAL CANCER; CISPLATIN-RESISTANCE; LIPOSOMAL CISPLATIN; MIGRATION; SPHEROIDS;

ALDEHYDE DEHYDROGENASE; ANIMALS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CELL MOVEMENT; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HELA CELLS; HUMANS; LIPOSOMES; MICE; MICE, NUDE; MITOCHONDRIA; NEOPLASTIC STEM CELLS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SPHEROIDS, CELLULAR; THIOREDOXIN-DISULFIDE REDUCTASE; UTERINE CERVICAL NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84888305375     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.08.041     Document Type: Article

References (33)

1. C.A. Leath III, and J.M. Straughn Jr. Chemotherapy for advanced and recurrent cervical carcinoma: results from cooperative group trials Gynecol Oncol 129 1 2013 251 257
2. S.M. Sancho-Martinez, L. Prieto-Garcia, M. Prieto, J.M. Lopez-Novoa, and F.J. Lopez-Hernandez Subcellular targets of cisplatin cytotoxicity: an integrated view Pharmacol Ther 136 1 2012 35 55
3. T. Huo, R.F. Barth, W. Yang, R.J. Nakkula, R. Koynova, and B. Tenchov Preparation, biodistribution and neurotoxicity of liposomal cisplatin following convection enhanced delivery in normal and F98 glioma bearing rats PLoS One 7 11 2012 e48752
4. S. Zalba, and M.J. Garrido Liposomes, a promising strategy for clinical application of platinum derivatives Expert Opin Drug Deliv 10 6 2013 829 844
5. G.P. Stathopoulos, and T. Boulikas Lipoplatin formulation review article J Drug Deliv 2012 2012 581363
6. T. Boulikas Clinical overview on lipoplatin: a successful liposomal formulation of cisplatin Expert Opin Investig Drugs 18 2009 1197 1218
7. F.S. Farhat, S. Temraz, J. Kattan, K. Ibrahim, N. Bitar, and N. Haddad A phase II study of lipoplatin (liposomal cisplatin)/vinorelbine combination in HER-2/neu-negative metastatic breast cancer Clin Breast Cancer 11 2011 384 389
8. T.C. Chou, and P. Talalay Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors Adv Enzyme Regul 22 1984 27 55
9. L. Cattaruzza, D. Fregona, M. Mongiat, L. Ronconi, A. Fassina, and A. Colombatti Antitumor activity of gold(III)-dithiocarbamato derivatives on prostate cancer cells and xenografts Int J Cancer 128 1 2011 206 215
10. C.C. Liang, A.Y. Park, and J.L. Guan In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro Nat Protoc 2 2007 329 333
11. P. Spessotto, K. Lacrima, P.A. Nicolosi, E. Pivetta, M. Scapolan, and R. Perris Fluorescence-based assays for in vitro analysis of cell adhesion and migration Methods Mol Biol 522 2009 221 250
12. A. Ivascu, and M. Kubbies Rapid generation of single-tumor spheroids for high-throughput cell function and toxicity analysis J Biomol Screen 11 2006 922 932
13. Y.T. Phung, D. Barbone, V.C. Broaddus, and M. Ho Rapid generation of in vitro multicellular spheroids for the study of monoclonal antibody therapy J Cancer 2 2011 507 514
14. A. Brozovic, A. Ambriovic-Ristov, and M. Osmak The relationship between cisplatin-induced reactive oxygen species, glutathione, and BCL-2 and resistance to cisplatin Crit Rev Toxicol 40 2010 347 359
15. D.F. Mahmood, A. Abderrazak, E.H. Khadija, T. Simmet, and M. Rouis The thioredoxin system as a therapeutic target in human health and disease Antioxid Redox Signal 2013 ahead of print. http://dx.doi.org/10.1089/ars.2012.4757 (in press)
16. T. Soonthornthum, H. Arias-Pulido, N. Joste, L. Lomo, C. Muller, and T. Rutledge Epidermal growth factor receptor as a biomarker for cervical cancer Ann Oncol 22 2011 2166 2178
17. E. Sugihara, and H. Saya Complexity of cancer stem cells Int J Cancer 132 6 2013 1249 1259
18. J. Lopez, G. Ruiz, J. Organista-Nava, P. Gariglio, and A. Garcia-Carranca Human papillomavirus infections and cancer stem cells of tumors from the uterine cervix Open Virol J 6 2012 232 240
19. C.C. Wu, and S.B. Bratton Regulation of the intrinsic apoptosis pathway by reactive oxygen species Antioxid Redox Signal 19 6 2013 546 558
20. R.J. Youle, and A. Strasser The BCL-2 protein family: opposing activities that mediate cell death Nat Rev Mol Cell Biol 9 2008 47 59
21. W. Cai, B. Zhang, D. Duan, J. Wu, and J. Fang Curcumin targeting the thioredoxin system elevates oxidative stress in HeLa cells Toxicol Appl Pharmacol 262 2012 341 348
22. Y. Liu, Y. Li, S. Yu, and G. Zhao Recent advances in the development of thioredoxin reductase inhibitors as anticancer agents Curr Drug Targets 13 2012 1432 1444
23. T. Sasada, H. Nakamura, S. Ueda, N. Sato, Y. Kitaoka, and Y. Gon Possible involvement of thioredoxin reductase as well as thioredoxin in cellular sensitivity to cis-diamminedichloroplatinum (II) Free Radic Biol Med 27 1999 504 514
24. R. Narayanan, H.N. Kim, N.K. Narayanan, D. Nargi, and B. Narayanan Epidermal growth factor-stimulated human cervical cancer cell growth is associated with EGFR and cyclin D1 activation, independent of COX-2 expression levels Int J Oncol 40 2012 13 20
25. K. Iida, K. Nakayama, M.T. Rahman, M. Rahman, M. Ishikawa, and A. Katagiri EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target Br J Cancer 105 2011 420 427
26. T. Murata, H. Mizushima, I. Chinen, H. Moribe, S. Yagi, and R.M. Hoffman HB-EGF and PDGF mediate reciprocal interactions of carcinoma cells with cancer-associated fibroblasts to support progression of uterine cervical cancers Cancer Res 71 2011 6633 6642
27. A. Ahsan, S. Hiniker, S. Ramanand, S. Nyati, A. Hegde, and A. Helman Role of EGFR degradation in cisplatin-induced cytotoxicity in head and neck cancer Cancer Res 70 7 2010 2862 2869
28. K. Scatchard, J.L. Forrest, M. Flubacher, P. Cornes, and C. Williams Chemotherapy for metastatic and recurrent cervical cancer Cochrane Database Syst Rev 10 2012 CD006469
29. A.P. Chahinian, L. Norton, J.F. Holland, L. Szrajer, and R.D. Hart Experimental and clinical activity of mitomycin C and cis- diamminedichloroplatinum in malignant mesothelioma Cancer Res 44 1984 1688 1692
30. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, J. Stathopoulos, K. Marosis, and P. Michalopoulou Comparison of liposomal cisplatin versus cisplatin in non-squamous cell non-small-cell lung cancer Cancer Chemother Pharmacol 68 4 2011 945 950
31. N. Mylonakis, A. Athanasiou, N. Ziras, J. Angel, A. Rapti, and S. Lampaki Phase II study of liposomal cisplatin (Lipoplatin) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer Lung Cancer 68 2 2010 240 247
32. G.P. Stathopoulos, D. Antoniou, J. Dimitroulis, P. Michalopoulou, A. Bastas, and K. Marosis Liposomal cisplatin combined with paclitaxel versus cisplatin and paclitaxel in non-small-cell lung cancer: a randomized phase III multicenter trial Ann Oncol 21 11 2010 2227 2232
33. G. Charest, B. Paquette, D. Fortin, D. Mathieu, and L. Sanche Concomitant treatment of F98 glioma cells with new liposomal platinum compounds and ionizing radiation J Neurooncol 97 2 2010 187 193